0001209191-16-095842.txt : 20160204 0001209191-16-095842.hdr.sgml : 20160204 20160204185227 ACCESSION NUMBER: 0001209191-16-095842 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160202 FILED AS OF DATE: 20160204 DATE AS OF CHANGE: 20160204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEIDEN JEFFREY M CENTRAL INDEX KEY: 0001242825 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 161389823 MAIL ADDRESS: STREET 1: 40 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-02-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001242825 LEIDEN JEFFREY M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2016-02-02 4 A 0 53817 0.01 A 271719 D Common Stock 2016-02-03 4 S 0 4200 89.91 D 267519 D Common Stock 2016-02-03 4 S 0 3700 91.01 D 263819 D Common Stock 2016-02-03 4 S 0 900 91.96 D 262919 D Common Stock 2016-02-03 4 S 0 1034 92.87 D 261885 D Common Stock 440 I 401(k) Stock Option (Right to Buy) 91.05 2016-02-02 4 A 0 107276 0.00 A 2026-02-01 Common Stock 107276 107276 D Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $89.91 (range $89.31 to $90.27). Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $91.01 (range $90.37 to $91.33). Open market sales reported on this line occurred at a weighted average price of $91.96 (range $91.40 to $92.37). Open market sales reported on this line occurred at a weighted average price of $92.87 (range $92.50 to $93.11). The option vests in 16 quarterly installments from 02/02/2016. Omar White, Attorney-In-Fact 2016-02-04